Recall Register

Drug recall: Lansoprazole Delayed-Release Orally Disintegrating Tablets 15 mg, 100-count carton (10 x10 unit-dose), Rx only…

Class II FDA enforcement event 86663. Recall start date: . Status in the FDA record: Terminated. Termination date: .

Reason for recall, in the words of FDA

Failed Dissolution Specification

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

Zydus Pharmaceuticals (USA) Inc started this drug recall on 27 Oct 2020. The firm address in the FDA record is in Pennington, NJ. FDA put the recall in Class II. FDA event 86663 has 2 product records. The first FDA enforcement report date is 11 Nov 2020. The record gives the status Terminated, with the termination date 20 Dec 2022.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Distributed Nationwide in the USA

Recalling firm

Zydus Pharmaceuticals (USA) Inc, Pennington, NJ.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

2 product records in the event.

FDA event 86663: product records
Recall numberProductQuantityClassStatusReport date
D-0074-2021Lansoprazole Delayed-Release Orally Disintegrating Tablets 15 mg, 100-count carton (10 x10 unit-dose), Rx only, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India, Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534, NDC 68382-771-776,840 unitsClass IITerminated11 Nov 2020
D-0075-2021Lansoprazole Delayed-Release Orally Disintegrating Tablets 30 mg, 100-count carton (10 x10 unit-dose), Rx only, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India, Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534, NDC 68382-772-777,908 unitsClass IITerminated11 Nov 2020

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Drug events that started in 2020
342
Share of these events in Class II
64%
Product records in this event
2Median of the firm: 1
Events of the firm on the register
54

Other events of the firm

Other FDA enforcement events of Zydus Pharmaceuticals (USA) Inc
InitiatedProduct (first record)TypeClassRecords
5 Aug 2026Mirabegron Extended-Release Tablets, 25 mg, 30-count bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Matoda, DrugClass II1
29 Apr 2026Erythromycin Tablets, USP, 250 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, DrugClass II2
9 Mar 2026Icosapent Ethyl Capsules, 1 gram, 120 Capsules per bottle, Rx only, Manufactured by: Softgel Healthcare Pvt. Ltd., IndiaDrugClass II1
30 Dec 2025Icosapent Ethyl capsules, 1 gram, 120-count bottles, Rx only, Manufactured by: Softgel Healthcare Pvt. Ltd., India, DistDrugClass II1
19 Dec 2025traZODONE Hydrochloride Tablets, USP, 100mg, 1,000 Tablets, Rx only, Manufactured by: Zydus Lifesciences Ltd., India, DiDrugClass III1
23 Oct 2025Bromocriptine Mesylate Capsules, USP, 5 mg, 30 Capsules per bottle, Rx Only. Manufactured by: Zydus Lifesciences Ltd., ADrugClass II1
22 Oct 2025clomiPRAMINE Hydrochloride, Capsules, USP, 25 mg, packaged in a) 30-count bottles (NDC 16714-849-01), b) 90-count bottleDrugClass II3
24 Sep 2025Entecavir Tablets, USP, 0.5 mg, 30-count bottle, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, DiDrugClass II2
4 Sep 2025Entecavir Tablets, USP, 0.5 mg, 30 Tablets, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, DistribDrugClass II2
3 Sep 2025Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 100-count bottle, Rx only, Manufactured By: Zydus Lifesciences Ltd., BDrugClass II10

Zydus Pharmaceuticals (USA) Inc: all 54 events

Official channels

Cite this page

Recall Register. FDA enforcement event 86663. https://recallregister.com/fda/ii/86663/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Distributed Nationwide in the USA
What quantity of product is in FDA event 86663?
The event has 2 product records. The first record gives this quantity: 6,840 units
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2020 have the same class?
64% of the 342 drug events that started in 2020 are in Class II.